Overview A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies Status: Completed Trial end date: 2015-04-20 Target enrollment: Participant gender: Summary To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies. Phase: Phase 1 Details Lead Sponsor: Zenyaku Kogyo Co., Ltd.